JP Morgan Maintains Neutral on Teladoc Health, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill maintains a Neutral rating on Teladoc Health (NYSE:TDOC) but lowers the price target from $16 to $9.
August 26, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained a Neutral rating on Teladoc Health but significantly lowered the price target from $16 to $9, indicating a less optimistic outlook.
The reduction in the price target from $16 to $9 by JP Morgan suggests a negative outlook on Teladoc's future performance, likely leading to a short-term decrease in stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100